SEC Insider Transactions from Sullivan Christopher Ryan.

Last updated: 2026-05-11 21:13 UTC | Total transactions: 30

Sullivan Christopher Ryan has filed 30 insider transactions across 1 company since February 2023.

Most recent transaction: a option exercise of 18606 shares of Avalo Therapeutics, Inc. ($AVTX) on May 07, 2026.

Activity breakdown: 1 open-market purchase and 12 sales.

Set Up your own filters →
Transaction Date Company Ticker Insider Name Title Transaction Type Security Shares Price Shares Owned Following Total Shares Outstanding % of Owned % of Outstanding
May 7, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Stock Option (Right to Buy) 18606 $0.00 168,094.0000 18,133,968 9.97% 0.10%
May 7, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 18606 $24.12 423.0000 18,133,968 97.78% 0.10%
May 7, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Common Stock 18606 $9.88 19,029.0000 18,133,968 4398.58% 0.10%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 9219 $21.37 9,323.0000 18,133,968 49.72% 0.05%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 2700 $20.76 18,542.0000 18,133,968 12.71% 0.01%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 12347 $19.28 21,242.0000 18,133,968 36.76% 0.07%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Common Stock 47000 $8.04 47,423.0000 18,133,968 9999.99% 0.26%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 13834 $18.55 33,589.0000 18,133,968 29.17% 0.08%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Stock Option (Right to Buy) 47000 $0.00 116,000.0000 18,133,968 28.83% 0.26%
May 6, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 8900 $22.57 423.0000 18,133,968 95.46% 0.05%
April 30, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 8457 $13.23 423.0000 18,133,968 95.24% 0.05%
April 29, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 8458 $13.09 8,880.0000 18,133,968 48.78% 0.05%
April 1, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 7479 $16.83 25,318.0000 18,133,968 22.80% 0.04%
April 1, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 500 $15.86 32,797.0000 18,133,968 1.50% 0.00%
April 2, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 6200 $17.02 19,118.0000 18,133,968 24.49% 0.03%
April 2, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer S Common Stock 1780 $17.57 17,338.0000 18,133,968 9.31% 0.01%
March 28, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Restricted Stock Units 24200 $0.00 24,200.0000 18,133,968 50.00% 0.13%
March 28, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer F Common Stock 8241 $13.89 33,297.0000 18,133,968 19.84% 0.05%
March 28, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Common Stock 24200 $0.00 41,538.0000 18,133,968 139.58% 0.13%
Feb. 26, 2026 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Stock Option (Right to Buy) 105000 $0.00 105,000.0000 18,133,968 9999.99% 0.58%
Dec. 10, 2025 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer F Common Stock 155 $4.10 17,338.0000 18,133,968 0.89% 0.00%
March 28, 2025 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Restricted Stock Units 24200 $0.00 48,400.0000 10,671,934 33.33% 0.23%
March 28, 2025 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer F Common Stock 7285 $8.46 16,921.0000 10,671,934 30.10% 0.07%
March 28, 2025 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer M Common Stock 24200 $0.00 24,206.0000 10,671,934 9999.99% 0.23%
Jan. 28, 2025 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Stock Option (Right to Buy) 163000 $0.00 163,000.0000 0 9999.99% 0.00%
Aug. 13, 2024 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Restricted Stock Units 72600 $0.00 72,600.0000 0 9999.99% 0.00%
Aug. 13, 2024 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Stock Option (Right to Buy) 186700 $0.00 186,700.0000 0 9999.99% 0.00%
June 9, 2023 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer P Common Stock 511 $3.42 1,262.0000 0 68.04% 0.00%
May 15, 2023 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Stock Option (Right to Buy) 40000 $0.00 40,000.0000 0 9999.99% 0.00%
Feb. 13, 2023 Avalo Therapeutics, Inc. $AVTX Sullivan Christopher Ryan Chief Financial Officer A Stock Option (Right to Buy) 40000 $0.00 40,000.0000 0 9999.99% 0.00%